Hologic, Inc. (HOLX) is considered a
trending stock currently. Despite daily gains and losses, it often outperforms competitors. Major investment advisories, including
Steward Partners Investment Advisory LLC and
US Bancorp DE, have sold shares, while others like
Corient Private Wealth LLC and
PNC Financial Services Group Inc. increased their positions. Hologic has entered oversold territory, yet it's recommended by Wall Street analysts. Within its product portfolio, Hologic launched its
CE-Marked Fluent System in Europe and recalled BioZorb Markers due to injury risk. Despite challenging situations, Hologic consistently surpasses estimates with their Q1 and Q2 earnings, boosted by non-COVID diagnostic sales. Its fiscal Q1 2024 earnings not only exceeded guidance but also raised its full-year outlook. Notably,
Director Scott Garrett sold 16,441 HOLX shares, and there are speculations of potential weaknesses due to insider selling. However, Hologic looks poised for growth with strong fundamentals. Additionally, Hologic recently acquired Endomagnetics Ltd, a breast surgical company, and announced plans to shutter some facilities within its diagnostics unit. It debuted presentations at several upcoming investor conferences and announced webcasts for multiple fiscal quarter earnings results.
Hologic HOLX News Analytics from Thu, 07 Nov 2019 08:00:00 GMT to Sun, 02 Jun 2024 15:04:18 GMT -
Rating 5
- Innovation 8
- Information 6
- Rumor 4
